NCT07762703
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07762703
Title Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors BreakBio Corp
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Miami Herbert Wertheim Cancer Institute Miami Florida 33176 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field